Sharps Technology Inc (STSS) is experiencing growth in their stock prices on Friday, with a high volume of 15.17 million shares traded. This comes after the company recently received two purchase orders for approximately 1 million SecureGard ultra-low waste smart safety syringes produced at their facility in Hungary. The first shipment of 100k syringes is scheduled for the third week of July, with subsequent deliveries planned throughout the rest of 2024. The undisclosed customer is a Swiss-based provider of cosmetic, dental, and ophthalmic injectable therapies.
The demand for innovative injection solutions is increasing rapidly, with injectables being widely used in therapies such as vaccines, biologics, weight loss and maintenance, ophthalmic and cosmetic applications, gene therapies, and diabetes and inflammatory disease management. Sharps has gained attention due to market growth and issues with Chinese-supplied syringes, such as tariffs, recalls, and quality concerns. This has led to growing interest and potential demand for Sharps’ high-quality smart safety syringe products.
Sharps Technology specializes in the development and manufacturing of drug delivery systems, focusing on low-waste and ultra-low waste syringe technologies with active safety features and re-use prevention measures accredited by the World Health Organization. These features protect healthcare workers from needle stick injuries and the public from the risks of needle re-use. Additionally, Sharps has a manufacturing facility in Hungary and is finalizing an asset acquisition in South Carolina to expand their manufacturing capacity in the U.S.
Overall, the recent orders for SecureGard syringes highlight the potential for growth and collaboration for Sharps Technology Inc as they continue to develop innovative solutions to meet the evolving needs of the healthcare industry.
